First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. Zhou C, Solomon B, Loong HH, Park K, et al. N Engl J Med 2023;389:1839-1850.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhou C, Solomon B, Loong HH, Park K, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med 2023;389:1839-1850.
PMID: 37870973